BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks